![Ian Churcher](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ian Churcher
Chief Tech/Sci/R&D Officer at Amphista Therapeutics Ltd.
Ian Churcher active positions
Companies | Position | Start | End |
---|---|---|---|
Amphista Therapeutics Ltd.
![]() Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Chief Tech/Sci/R&D Officer | 2023-05-01 | - |
Career history of Ian Churcher
Statistics
International
United Kingdom | 2 |
Operational
Chief Tech/Sci/R&D Officer | 1 |
Sectoral
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Amphista Therapeutics Ltd.
![]() Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Health Technology |
- Stock Market
- Insiders
- Ian Churcher
- Experience